title: Targeted programmed cell death in lung cancer treatment.
authors.affiliation: CVS Caremark.
authors.forename: Marj P
authors.initials: MP
authors.lastname: Zimmerman
authors.forename: Stanton R
authors.initials: SR
authors.lastname: Mehr
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D060890:B7-H1 Antigen / Q000187:drug effects / Q000276:immunology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D002423:Cause of Death; D017321:Clinical Trials, Phase I as Topic; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D000074324:Ipilimumab; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D008297:Male; D000077594:Nivolumab; D011379:Prognosis; D012907:Smoking / Q000009:adverse effects*; D015996:Survival Rate; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D007155:Immunologic Factors; D000074324:Ipilimumab; D000077594:Nivolumab